- Home
- AIRI vs PULM Comparison
AIRI vs PULM Comparison
Compare AIRI & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRI
- PULM
- Stock Information
- Founded
- AIRI 1979
- PULM 2003
- Country
- AIRI United States
- PULM United States
- Employees
- AIRI N/A
- PULM N/A
- Industry
- AIRI Military/Government/Technical
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- AIRI Industrials
- PULM Health Care
- Exchange
- AIRI Nasdaq
- PULM Nasdaq
- Market Cap
- AIRI 15.4M
- PULM 18.3M
- IPO Year
- AIRI N/A
- PULM N/A
- Fundamental
- Price
- AIRI $3.14
- PULM $4.80
- Analyst Decision
- AIRI
- PULM
- Analyst Count
- AIRI 0
- PULM 0
- Target Price
- AIRI N/A
- PULM N/A
- AVG Volume (30 Days)
- AIRI 46.5K
- PULM 11.5K
- Earning Date
- AIRI 11-13-2025
- PULM 10-16-2025
- Dividend Yield
- AIRI N/A
- PULM N/A
- EPS Growth
- AIRI N/A
- PULM N/A
- EPS
- AIRI N/A
- PULM N/A
- Revenue
- AIRI $52,277,000.00
- PULM $3,000.00
- Revenue This Year
- AIRI N/A
- PULM N/A
- Revenue Next Year
- AIRI $3.53
- PULM $134.88
- P/E Ratio
- AIRI N/A
- PULM N/A
- Revenue Growth
- AIRI N/A
- PULM N/A
- 52 Week Low
- AIRI $2.80
- PULM $2.00
- 52 Week High
- AIRI $6.28
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- AIRI 44.03
- PULM 47.03
- Support Level
- AIRI $3.02
- PULM $4.55
- Resistance Level
- AIRI $3.33
- PULM $4.97
- Average True Range (ATR)
- AIRI 0.10
- PULM 0.17
- MACD
- AIRI -0.02
- PULM 0.00
- Stochastic Oscillator
- AIRI 36.44
- PULM 33.58
About AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).